Matches in Wikidata for { <http://www.wikidata.org/entity/Q65540774> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q65540774 description "clinical trial" @default.
- Q65540774 description "ensayu clínicu" @default.
- Q65540774 description "klinisch onderzoek" @default.
- Q65540774 description "клінічне випробування" @default.
- Q65540774 name "TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Lim" @default.
- Q65540774 name "TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Lim" @default.
- Q65540774 type Item @default.
- Q65540774 label "TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Lim" @default.
- Q65540774 label "TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Lim" @default.
- Q65540774 prefLabel "TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Lim" @default.
- Q65540774 prefLabel "TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Lim" @default.
- Q65540774 P1132 Q65540774-7A42C3BB-97A7-4DD7-99DC-7CC75A75BF7B @default.
- Q65540774 P1476 Q65540774-0B2167F4-64F0-47B1-84EC-6638ED225523 @default.
- Q65540774 P2899 Q65540774-7BD0D255-9D33-4F40-815C-919C1F004449 @default.
- Q65540774 P3098 Q65540774-FCE36A1F-2A90-4E53-8C72-2A6B135D4B92 @default.
- Q65540774 P31 Q65540774-986684E6-971E-4E1E-8B1A-98F4E9459F41 @default.
- Q65540774 P4844 Q65540774-0EA95B7E-53DB-455B-B953-F45F11598EE2 @default.
- Q65540774 P4844 Q65540774-5E16461A-BAEF-4584-901E-42920B6BB6CB @default.
- Q65540774 P580 Q65540774-1C50C4F6-C445-4483-A45B-00F81BBABE9D @default.
- Q65540774 P582 Q65540774-3E3A3A1C-C4F8-4F3F-AF8B-08C4B5DE7E9E @default.
- Q65540774 P6099 Q65540774-022B6EA3-5BE2-4625-8AD6-7D8D9F21469B @default.
- Q65540774 P8363 Q65540774-38E54600-4627-4AB9-B753-798A8BB25036 @default.
- Q65540774 P1132 "+593" @default.
- Q65540774 P1476 "A Phase III Randomized, Double-blinded, Placebo-controlled Trial to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an ART Regimen, Including TMC114/RTV and an Investigator-selected OBR, in HIV-1 Infected Patients With Limited Treatment to no Treatment Options." @default.
- Q65540774 P2899 "+18" @default.
- Q65540774 P3098 "NCT00255099" @default.
- Q65540774 P31 Q30612 @default.
- Q65540774 P4844 Q3765251 @default.
- Q65540774 P4844 Q414762 @default.
- Q65540774 P580 "2005-12-01T00:00:00Z" @default.
- Q65540774 P582 "2007-01-01T00:00:00Z" @default.
- Q65540774 P6099 Q42824827 @default.
- Q65540774 P8363 Q78089383 @default.